Overlap of Gestational Diabetes Mellitus and Pre-eclampsia: A Scoping Review.

IF 4.2 3区医学 Q2 Medicine

Diabetes Therapy Pub Date : 2026-07-01 Epub Date: 2026-06-15 DOI:10.1007/s13300-026-01880-6

Lunghar Janeline, Thyparambil Aravindakshan PramodKumar, Mohan Deepa, Balaji Bhavadharini, Uddhav Chaudhari, Geetanjali Sachdeva, Sadhana Joshi, Haritha Sagili, Anish Keepanasseril, Sadish Kumar Kamalanathan, Polina Popova, Ponnusamy Saravanan, Uma Ram, Ranjit Unnikrishnan, Ranjit Mohan Anjana, Viswanathan Mohan

{"title":"Overlap of Gestational Diabetes Mellitus and Pre-eclampsia: A Scoping Review.","authors":"Lunghar Janeline, Thyparambil Aravindakshan PramodKumar, Mohan Deepa, Balaji Bhavadharini, Uddhav Chaudhari, Geetanjali Sachdeva, Sadhana Joshi, Haritha Sagili, Anish Keepanasseril, Sadish Kumar Kamalanathan, Polina Popova, Ponnusamy Saravanan, Uma Ram, Ranjit Unnikrishnan, Ranjit Mohan Anjana, Viswanathan Mohan","doi":"10.1007/s13300-026-01880-6","DOIUrl":null,"url":null,"abstract":"<p><p>Gestational diabetes mellitus (GDM) and preeclampsia (PE) are among the most common medical complications in pregnancy, with prevalence rates of 10-25% and 3-9.4%, respectively. Both conditions are important causes of maternal and neonatal morbidity and pose considerable risks to maternal and fetal health. GDM and PE are traditionally viewed as distinct clinical entities. However, they share several common risk factors, including advanced maternal age, obesity, family history of metabolic disease, dyslipidemia and genetic predisposition. The two conditions also have overlapping pathophysiological pathways, particularly involving metabolic and vascular dysfunctions such as insulin resistance, chronic inflammation and endothelial dysfunction. This article reviews the prevalence of GDM and PE, the risk factors common to the two conditions and biomarkers that may aid in early identification of these disorders. The report also discusses clinical implications of the overlap between the two disorders, with a plea for integrated management strategies. Finally, the article also highlights potential preventive measures and underscores the importance of multidisciplinary approaches to improve pregnancy outcomes in those with GDM and PE.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":"937-958"},"PeriodicalIF":4.2000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13388582/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13300-026-01880-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Gestational diabetes mellitus (GDM) and preeclampsia (PE) are among the most common medical complications in pregnancy, with prevalence rates of 10-25% and 3-9.4%, respectively. Both conditions are important causes of maternal and neonatal morbidity and pose considerable risks to maternal and fetal health. GDM and PE are traditionally viewed as distinct clinical entities. However, they share several common risk factors, including advanced maternal age, obesity, family history of metabolic disease, dyslipidemia and genetic predisposition. The two conditions also have overlapping pathophysiological pathways, particularly involving metabolic and vascular dysfunctions such as insulin resistance, chronic inflammation and endothelial dysfunction. This article reviews the prevalence of GDM and PE, the risk factors common to the two conditions and biomarkers that may aid in early identification of these disorders. The report also discusses clinical implications of the overlap between the two disorders, with a plea for integrated management strategies. Finally, the article also highlights potential preventive measures and underscores the importance of multidisciplinary approaches to improve pregnancy outcomes in those with GDM and PE.

查看原文本刊更多论文

妊娠期糖尿病和先兆子痫的重叠：一项范围审查。

妊娠期糖尿病（GDM）和先兆子痫（PE）是妊娠期最常见的并发症，患病率分别为10-25%和3-9.4%。这两种情况都是孕产妇和新生儿发病的重要原因，并对孕产妇和胎儿健康构成相当大的风险。GDM和PE传统上被视为不同的临床实体。然而，她们有几个共同的危险因素，包括高龄产妇、肥胖、代谢疾病家族史、血脂异常和遗传易感性。这两种疾病也有重叠的病理生理途径，特别是涉及代谢和血管功能障碍，如胰岛素抵抗、慢性炎症和内皮功能障碍。本文综述了GDM和PE的患病率，两种疾病共同的危险因素以及可能有助于早期识别这些疾病的生物标志物。该报告还讨论了两种疾病重叠的临床意义，并呼吁采取综合管理策略。最后，文章还强调了潜在的预防措施，并强调了多学科方法改善GDM和PE患者妊娠结局的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes Therapy Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

6.90

自引率

7.90%

发文量

130

审稿时长

6 weeks

期刊介绍： Diabetes Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all areas of diabetes. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Diabetes Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.